TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9368804

Group type: COMPARATOR
Intervention: 0 g added triglycerides
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 g added triglycerides
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30 g added triglycerides
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 g added triglycerides
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All triglyceride amounts (0, 15, 30, 40 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 15 g or more added triglycerides
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0 to 40 g added triglycerides
Number of subjects: 8
Study: 7692173

Group type: EXPERIMENTAL
Intervention: Isradipine regular formulation (RF) 2.5 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isradipine modified release (MR) 5 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3955199

Group type: EXPERIMENTAL
Intervention: Intravenous prenalterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release formulation of prenalterol
Number of subjects: 0
Study: 31724351

Group type: EXPERIMENTAL
Intervention: Grain-moxibustion at Zusanli (ST 36) and Weishu (BL 21), 9 cones for each acupoint, once a day for 90 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional chemotherapy regimen combined with symptomatic treatment (antiemetic, acid-suppressive, liver-protecting drugs).
Number of subjects: 60
Study: 28478653

Group type: EXPERIMENTAL
Intervention: Venlafaxine-lithium treatment strategy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Imipramine-lithium treatment strategy
Number of subjects: 88
Study: 25415373

Group type: EXPERIMENTAL
Intervention: Fixed fluence (FF) treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Judged fluence (JF) treatment
Number of subjects: 14
Study: 23086494

Group type: EXPERIMENTAL
Intervention: Regenerated mastoid air cells (MACs)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Unregenerated mastoid air cells (MACs)
Number of subjects: 76
Study: 21654918

Group type: EXPERIMENTAL
Intervention: In-home training for fathers, skills taught: following the child's lead, imitation with animation, commenting on the child, expectant waiting, duration: 12 weeks, frequency: twice a week
Number of subjects: 18
Study: 18490576

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17042843

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (30 mg x kg(‐1) before induction, 10 mg x kg(‐1) continuously intra‐operatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline (same volume as magnesium group)
Number of subjects: 50
Study: 12895688

Group type: EXPERIMENTAL
Intervention: Panax ginseng (200 mg G115)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (360 mg GK501)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10973403

Group type: EXPERIMENTAL
Intervention: Voluntary coughing (once every 30 seconds for 15 to 30 minutes)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study: 8942562

Group type: EXPERIMENTAL
Intervention: CT > 60 (cadaveric transplant from older donor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LT < 50 (living donor transplant from younger donor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LT > 60 (living donor transplant from older donor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CT < 50 (cadaveric transplant from younger donor)
Number of subjects: 24
Study: 1281041

Group type: EXPERIMENTAL
Intervention: L-TAE + ADR
Number of subjects: 289

Group type: COMPARATOR
Intervention: L-TAE
Number of subjects: 289
Study: 6235336

Group type: EXPERIMENTAL
Intervention: Megadoses of vitamins with minerals
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study: 30831308

Group type: EXPERIMENTAL
Intervention: Hypnosis (audio session, 26 minutes)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 148
Study: 30273343

Group type: EXPERIMENTAL
Intervention: Community-wide biannual treatment with mass drug administration (MDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual treatment of children alone with MDA
Number of subjects: 0
Study: 27052303

Group type: EXPERIMENTAL
Intervention: ECC-overload flywheel resistance exercise (12 weeks, 2 times/week; 4 sets of 7 maximal closed-chain knee extensions; <2 min of contractile activity per session)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECC-overload flywheel resistance exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (maintaining daily routines)
Number of subjects: 32
Study: 24419000

Group type: EXPERIMENTAL
Intervention: Post-stroke shoulder pain group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Stroke groups (with and without shoulder pain)
Number of subjects: 49
Study: 21917058

Group type: EXPERIMENTAL
Intervention: air-Q intubating laryngeal airway (ILA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway‐Unique (LMA‐U)
Number of subjects: 50
Study: 20144497

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-PRF treatment (control)
Number of subjects: 14
Study: 17878468

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (including exercise training, education, psychosocial support, and nutritional intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of optimal bronchodilator therapy and/or supplemental oxygen therapy with exercise training
Number of subjects: 0
Study: 16344836

Group type: EXPERIMENTAL
Intervention: MAS XR 30 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: MAS XR 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: MAS XR 40 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: MAS XR 60 mg
Number of subjects: 32
Study: 12117301

Group type: EXPERIMENTAL
Intervention: Hyperhydration induced by ingestion of glycerol (1.1 g/kg body mass) and fluid (21.4 mL/kg body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Euhydration (control trial)
Number of subjects: 8
Study: 11697710

Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate (ADP) induced platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen induced platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean platelet count before therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ristocetin induced platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine induced platelet aggregation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADP and collagen induced platelet aggregations
Number of subjects: 0
Study: 9597244

Group type: COMPARATOR
Intervention: Four-drug regimen (standard treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five-drug regimen (four drugs plus levofloxacin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 months of intermittent therapy with isoniazid and rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 months of intermittent therapy with isoniazid and rifampin
Number of subjects: 0
Study: 7939999

Group type: EXPERIMENTAL
Intervention: Spinal fusion for idiopathic scoliosis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Spinal fusion for degenerative scoliosis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Spinal fusion (overall)
Number of subjects: 53
Study: 3108009

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Nitroderm‐TTS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Transmucosal nitroglycerin (Trinitrolong)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 9
Study: 31278521

Group type: EXPERIMENTAL
Intervention: LAD lesions
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: LCx lesions
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: RCA lesions
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: εs (LAD, RCA) and GLS (LCx)
Number of subjects: 1235
Study: 29440149

Group type: EXPERIMENTAL
Intervention: Multimodal cachexia intervention (MENAC trial) including non-steroidal anti-inflammatory drugs, eicosapentaenoic acid, physical exercise program (resistance and aerobic training), dietary counselling, and oral nutritional supplements.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 28164458

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 38
Study: 26170027

Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (0.5%, 1%, and 3%) applied twice daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (3%) applied twice daily to a 100-cm² site for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion (3%) applied twice daily to a 500-cm² site for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lotion vehicle applied as control
Number of subjects: 0
Study: 23682979

Group type: EXPERIMENTAL
Intervention: Immediate antibiotic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription given to patient)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription left at the reception of the primary care centre 3 days after the first medical visit)
Number of subjects: 0
Study: 21845445

Group type: EXPERIMENTAL
Intervention: FRG-E (500 μg mouse(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: NFRG-E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FRG-E
Number of subjects: 0
Study: 19138952

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16652320

Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: IACM
Number of subjects: 250

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 250
Study: 12733686

Group type: EXPERIMENTAL
Intervention: Lowering intraocular pressure (IOP) through various treatments, specific interventions not detailed, duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setting and achieving a target IOP range, specific interventions not detailed, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11009854

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) technique
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Comparison group (no TM)
Number of subjects: 1418
Study: 8670711

Group type: EXPERIMENTAL
Intervention: Labeled Magnitude Scale (LMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnitude Estimation (ME)
Number of subjects: 0
Study: 1733754

Group type: EXPERIMENTAL
Intervention: Valproate therapy (VPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 31408474

Group type: EXPERIMENTAL
Intervention: Group I: delayed (> 3 months)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Group II: prompt (24-48 hours)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Group III: immediate (< 24 hours)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 1232
Study: 29996802

Group type: EXPERIMENTAL
Intervention: Lyophilised vaccines (BCG, Measles, Yellow Fever)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multi-dose/single dose vials of liquid vaccines
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Knowledge assessment of health workers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: National projected wastage targets
Number of subjects: 80
Study: 27514506

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) in fasted condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) 30 minutes after a high‐fat meal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone in fasted condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone 30 minutes after a high‐fat meal
Number of subjects: 48
Study: 24747488

Group type: EXPERIMENTAL
Intervention: Home-based Behavioral Activation for Depression (BATD) treatment delivered via web-based video technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-office Behavioral Activation for Depression (BATD) treatment
Number of subjects: 0
Study: 23285070

Group type: EXPERIMENTAL
Intervention: 100 mg L-dopa (Madopar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20469975

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg
Number of subjects: 698

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan 5/80 mg (subgroup n = 82)
Number of subjects: 698

Group type: COMPARATOR
Intervention: Amlodipine (subgroup n = 82)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan
Number of subjects: 698

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 698
Study: 17520207

Group type: EXPERIMENTAL
Intervention: Temporary unflanged pancreatic duct stent (5-Fr pigtail PS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no stenting)
Number of subjects: 64
Study: 15667798

Group type: EXPERIMENTAL
Intervention: Nicardipine combined with esmolol (1:10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitroglycerine combined with esmolol (1:10)
Number of subjects: 20
Study: 12410745

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10221486

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (1.5 mg/kg intravenously)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Atgam (15 mg/kg intravenously)
Number of subjects: 72
Study: 8590509

Group type: EXPERIMENTAL
Intervention: 13.5 mg hyperbaric bupivacaine 0.75% + 25 micrograms fentanyl intrathecal (Group II)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 13.5 mg hyperbaric bupivacaine 0.75% + 0.5 ml CSF (Group I)
Number of subjects: 43
Study: 2089295

Group type: EXPERIMENTAL
Intervention: Peridural analgo-anesthesia during labour and birth (continuous lumbar epidural block)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study: 108663

Group type: EXPERIMENTAL
Intervention: 10% dextrose in 0.225% NaCl
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10% dextrose-amino acid solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10% dextrose-amino acid with intravenous fat emulsion
Number of subjects: 6
Study: 31494019

Group type: EXPERIMENTAL
Intervention: Visual feedback intervention group
Number of subjects: 93

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 93
Study: 28215627

Group type: EXPERIMENTAL
Intervention: Weight management intervention with family member as study partner
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Weight management intervention with paid assistant as study partner
Number of subjects: 147

Group type: COMPARATOR
Intervention: Paid assistants as study partner
Number of subjects: 147
Study: 26192350

Group type: EXPERIMENTAL
Intervention: BCG needle and syringe (NS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biojector 2000® (B2000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioject ID Pen® (ID Pen)
Number of subjects: 0
Study: 23612881

Group type: EXPERIMENTAL
Intervention: ANEclear anesthesia recovery device
Number of subjects: 30
Study: 21623968

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - 200 μg beclomethasone extra-fine daily for 8 weeks
Number of subjects: 93
Study: 19218828

Group type: EXPERIMENTAL
Intervention: Single-family therapy (n = 25)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Multi-family group therapy (n = 35)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Treatment as usual (n = 23)
Number of subjects: 83
Study: 17462395

Group type: EXPERIMENTAL
Intervention: mini-CPB system
Number of subjects: 49

Group type: COMPARATOR
Intervention: standard CPB
Number of subjects: 49
Study: 14762447

Group type: EXPERIMENTAL
Intervention: Natural drying
Number of subjects: 109

Group type: COMPARATOR
Intervention: Alcohol (70% isopropyl)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 109
Study: 11672450

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lisinopril (5-20 mg daily)
Number of subjects: 69
Study: 9338727

Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG) 150 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) 54 MU
Number of subjects: 122
Study: 7909875

Group type: EXPERIMENTAL
Intervention: Relative risk reduction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Absolute risk reduction
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Percentages of event-free patients
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Number needed to treat
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Events reduction and mortality increase
Number of subjects: 148
Study: 3322922

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 285

Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.i.d.
Number of subjects: 285
Study: 28746246

Group type: EXPERIMENTAL
Intervention: Constant-Torque (CT) static stretching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Constant-Angle (CA) static stretching
Number of subjects: 30
Study: 27327970

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) alone (AER)
Number of subjects: 13

Group type: COMPARATOR
Intervention: HIIT combined with strength training (COM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both HIIT (AER) and HIIT combined with strength training (COM)
Number of subjects: 13
Study: 26365989

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 4152

Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (per additional 5% of calories)
Number of subjects: 4152
Study: 23507375

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg orally, administered 4 hours before a match)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (cellulose, administered 4 hours before a match)
Number of subjects: 12
Study: 21199686

Group type: COMPARATOR
Intervention: PV isolation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GP+PV ablation
Number of subjects: 67
Study: 20008243

Group type: EXPERIMENTAL
Intervention: Induction therapy with lenalidomide, bortezomib, and dexamethasone
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with a single autologous stem cell transplant
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 1
Study: 16824730

Group type: EXPERIMENTAL
Intervention: Eccentric exercise prior to influenza vaccination
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resting quietly (control group)
Number of subjects: 60
Study: 15108985

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, 11, or 12 mg) with 10 microg intrathecal fentanyl and 200 microg intrathecal morphine
Number of subjects: 42
Study: 11268890

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTO)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pharmacological management
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Surgical therapy (bilateral reduction of lung volume)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nutritional therapy (special diets)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Psycho-social interventions (e.g. psychotherapy, training and education)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Rehabilitation programs (variety of interventions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 31
Study: 9847435

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Racemic albuterol 1.25 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 7974381

Group type: EXPERIMENTAL
Intervention: Trisodium citrate 129 mM
Number of subjects: 5

Group type: COMPARATOR
Intervention: Trisodium citrate 109 mM
Number of subjects: 5
Study: 2566735

Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening test
Number of subjects: 107349

Group type: EXPERIMENTAL
Intervention: Rescreening every 2 years
Number of subjects: 107349

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 107349
Study: 31712994

Group type: EXPERIMENTAL
Intervention: Hinge craniotomy (HC)
Number of subjects: 283
Study: 30106321

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Lipid-lowering agents
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Duration of stay in nursing home ≤10 months
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Duration of stay in nursing home 11-21 months
Number of subjects: 218